ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 899

Changes in the Systemic Sclerosis Molecular Signatures after Myeloablation Followed By Autologous Hematopoietic Stem Cell Transplantation and Their Clinical Correlates

Shervin Assassi1, Xuan Wang2, Jun Ying3, Lynette Keyes-Elstein4, Ellen Goldmuntz5, Jacob Turner6, Wenjin Zheng7, Guocai Chen7, Maria Virginia Pascual8, John Varga9, Monique Hinchcliff10, Chiara Bellocchi11, Peter McSweeney12, Daniel E. Furst13, Richard Nash12, Leslie Crofford14, Beverly Welch15, Ashley Pinckney16, Maureen D. Mayes1 and Keith Sullivan17, 1Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 2Baylor Scott & White Health, Dallas, TX, 3Department of Internal Medicine - Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 4Rho, Inc, Chapel Hill, NC, 5NIAID, National Institutes of Health, Bethesda, MD, 6Stephen F Austin University, Nacogdoches, TX, 7University of Texas Health Science Center at Houston, Houston, TX, 8Drukier Institute for Children's Health, Weill Cornell Medicine, New York, NY, 9Northwestern University, Chicago, IL, 10Rheumatology, Northwestern University, Chicago, IL, 11Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 12Colorado Blood Cancer Institute, Denver, CO, 13University of California Los Angeles, Los Angeles, CA, 14Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 15National Institutes of Health, Bethesda, MD, 16Rho Federal Systems, Inc., Chapel Hill, NC, 17Duke University Medical Center, Durham, NC

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Gene Expression, proteomics, stem cells and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S089 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical I: Clinical Trials I (898–903)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Myeloablation followed by autologous hematopoietic stem cell transplantation (HSCT) led to improved clinical outcomes compared to 12 monthly infusions of cyclophosphamide (CYC) in patients with severe diffuse systemic sclerosis (SSc) in SCOT trial1. Global molecular studies in SSc patients undergoing HSCT have not been reported. Herein, we suggest that HSCT leads to changes in SSc related immune signatures after immune recovery at 26 month visit at the whole blood RNA and serum protein levels.

Methods:

Sixty-two SCOT participants (HSCT= 27, CYC = 35) and 62 -matched controls were investigated.  Whole blood global transcript profiling and determination of 102 serum proteins in concomitantly collected serum samples were performed. All available samples at pretreatment baseline (n=62), 8 months (n=46), and 26 months (n=35) post-randomization were included.

Results:

This subset of SCOT participants had a mean disease duration of 2.2 years and 93.5% of them had interstitial lung disease.

At the baseline visit, two interferon (IFN) and one neutrophil transcript modules were upregulated and the cytotoxic/NK module was down-regulated in comparison to controls.  A paired comparison of the 26-month to the baseline samples revealed a significant decrease of the IFN and neutrophil modules and significant increase in the cytotoxic/NK module after HSCT but no significant change compared to baseline in the CYC recipients (Figure). Moreover, comparison of 26-month samples in the HSCT arm to healthy controls no longer showed upregulation of IFN or neutrophil modules or downregulation of cytotoxic/NK module. A decline in the IFN and neutrophil modules was associated with an improvement in lung volumes and an increase in the cytotoxic/NK module correlated with improvement in the skin score at 26-month (Table).

Serum proteins correlating with the IFN and neutrophil transcript modules were identified.  The serum protein IFN and neutrophil composite scores also decreased significantly at 26 months after HSCT (fold change (FC)=0.8, p <0.001; FC=0.85, p=0.003) while similar changes were not observed in the CYC arm at 8 or 26 months, confirming the gene expression level findings at the protein level. 

Conclusion:  

In this first multilevel, global molecular study of HSCT in SSc, HSCT recipients contrary to CYC recipients had significant changes in SSc molecular signatures at both the RNA and serum protein levels at Month 26. The results at Month 26 provide an interim look, but need to be validated at the Month 54 primary endpoint.

1.    Sullivan KM et al. NEJM 2018; 378:35-47

 

 

 

Table: Correlation of percent change in transcript modules with percent change in clinical outcome

Transcript module

FVC%

mRSS

r

p

r

p

M1.2 (IFN)

-0.43

0.012

0.12

0.5

M3.4 (IFN)

-0.39

0.023

0.06

0.745

M5.15 (neutrophil)

-0.37

0.035

0.03

0.853

M3.6 (Cytotoxic/NK cell)

0.14*

0.4334*

-0.53*

0.0014*

Abbreviations: FVC%: Forced vital capacity% predicted; mRSS: Modified Rodnan Skin Score

* Spearman’s Rho was used for this analysis

 


Disclosure: S. Assassi, Bayer, 2,Biogen Idec, 2,Boehringer Ingelheim, 2, 5,Momenta, 2; X. Wang, None; J. Ying, None; L. Keyes-Elstein, None; E. Goldmuntz, None; J. Turner, None; W. Zheng, None; G. Chen, None; M. V. Pascual, None; J. Varga, BSM, 2,Pfizer, Inc., 2,Boehringer, 5,Mitsubishi, 5,Corbus, 5,Scleroderma Foundation, 6; M. Hinchcliff, None; C. Bellocchi, None; P. McSweeney, None; D. E. Furst, no stocks, 2, 5, 6, 7; R. Nash, None; L. Crofford, None; B. Welch, None; A. Pinckney, None; M. D. Mayes, Boehringer-Ingelheim, 2, 5,Corbus, 2,Reata, 2,Sanofi, 2,Mitsubishi-Tanabe, 5,Roche-Genentech, 2; K. Sullivan, None.

To cite this abstract in AMA style:

Assassi S, Wang X, Ying J, Keyes-Elstein L, Goldmuntz E, Turner J, Zheng W, Chen G, Pascual MV, Varga J, Hinchcliff M, Bellocchi C, McSweeney P, Furst DE, Nash R, Crofford L, Welch B, Pinckney A, Mayes MD, Sullivan K. Changes in the Systemic Sclerosis Molecular Signatures after Myeloablation Followed By Autologous Hematopoietic Stem Cell Transplantation and Their Clinical Correlates [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/changes-in-the-systemic-sclerosis-molecular-signatures-after-myeloablation-followed-by-autologous-hematopoietic-stem-cell-transplantation-and-their-clinical-correlates/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-the-systemic-sclerosis-molecular-signatures-after-myeloablation-followed-by-autologous-hematopoietic-stem-cell-transplantation-and-their-clinical-correlates/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology